JERSEY CITY, N.J., Nov. 28, 2017 /PRNewswire/ -- SCYNEXIS, Inc.
(NASDAQ:SCYX), a biotechnology company delivering innovative
anti-infective therapies for difficult-to-treat and often
life-threatening infections, today announced that the Company will
participate in the following upcoming investor conferences:
- The Global Mizuho Investor Conference (MIC) NY at the Lotte New York Palace Hotel on
Monday, December 4, 2017.
- The Guggenheim Securities 5th Annual Boston
Healthcare Conference at the InterContinental Boston on
Wednesday, December 13, 2017.
About SCYNEXIS
SCYNEXIS, Inc. is a biotechnology
company committed to positively impacting the lives of
patients suffering from difficult-to-treat and often
life-threatening infections by delivering innovative anti-infective
therapies. The SCYNEXIS team has extensive experience in the life
sciences industry, discovering and developing more than 30
innovative medicines over a broad range of therapeutic areas. The
Company's lead product candidate, SCY-078, is the first
representative of a novel intravenous and oral triterpenoid
antifungal family and is in Phase 2 clinical development for the
treatment of several fungal infections, including serious and
life-threatening invasive fungal infections. For more
information, visit www.scynexis.com.
CONTACT:
Media Relations
Cammy Duong
MacDougall Biomedical Communications
Tel: 781-591-3443
cduong@macbiocom.com
Investor
Relations
Susan Kim
Argot Partners
Tel: 212-203-4433
susan@argotpartners.com
View original
content:http://www.prnewswire.com/news-releases/scynexis-to-participate-in-upcoming-investor-conferences-300562372.html
SOURCE SCYNEXIS, Inc.